Modality
Degrader
MOA
CDK4/6i
Target
TIGIT
Pathway
PD-1/PD-L1
Bladder CaCTCLPBC
Development Pipeline
Preclinical
~Jun 2017
→ ~Sep 2018
Phase 1
~Dec 2018
→ ~Mar 2020
Phase 2
~Jun 2020
→ ~Sep 2021
Phase 3
~Dec 2021
→ ~Mar 2023
NDA/BLA
~Jun 2023
→ ~Sep 2024
Approved
Dec 2024
→ Jan 2029
ApprovedCurrent
NCT08971054
1,739 pts·PBC
2025-04→2029-01·Completed
NCT07007021
681 pts·CTCL
2024-12→2028-05·Terminated
2,420 total pts2 indications
CompletedCurrentUpcoming
Catalysts (2)
2028-05-012.1y awayPh3 Readout· CTCL
2029-01-232.8y awayPh3 Readout· PBC
Trial Timeline
2025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
Approved
Termina…
Approved
Complet…
Catalysts
Ph3 Readout
2028-05-01 · 2.1y away
CTCL
Ph3 Readout
2029-01-23 · 2.8y away
PBC
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08971054 | Approved | PBC | Completed | 1739 | 6MWD |
| NCT07007021 | Approved | CTCL | Terminated | 681 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| RHH-1969 | Roche | Approved | BET | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| VRT-5441 | Vertex Pharma | Phase 3 | GLP-1R |